4basebio (4BB) Share Price, News & Analysis

Company Overview

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.

Key Stats

• Today's Range: 1,122.40 to 1,125
• 50-Day Range: 1,090.50 to 1,205
• 52-Week Range: 1,061 to 1,820
• Volume: 373 shs
• Average Volume: 1,038 shs
• Market Capitalization: £143.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 1,600
• Consensus Rating: Buy

4basebio Stock Analysis - MarketRank™

4basebio scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

4basebio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

4basebio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of 4basebio is -1,438.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 4basebio is -1,438.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for 4BB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

4basebio does not currently pay a dividend.

Dividend Growth

4basebio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for 4BB.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: N/A

News Sentiment

4basebio has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for 4basebio this week, compared to 0 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, 4basebio insiders have bought more of their company's stock than they have sold. Specifically, they have bought £41,811.20 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

68.44% of the stock of 4basebio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.04% of the stock of 4basebio is held by institutions.

4BB Stock Analysis - Frequently Asked Questions

How have 4BB shares performed this year?

4basebio's stock was trading at GBX 1,210 on January 1st, 2025. Since then, 4BB stock has decreased by 7.2% and is now trading at GBX 1,122.40.
View the best growth stocks for 2025 here.

How do I buy shares of 4basebio?

Shares of 4BB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of 4basebio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 4basebio investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), IQE (IQE) and Omega Diagnostics Group (ODX).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:4BB
• CIK: N/A
• Web: www.4basebio.com
• Phone: 44 1223 967 943
• Fax: N/A
• Employees: 101
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 1,600
• High Stock Price Target: GBX 1,600
• Low Stock Price Target: GBX 1,600
• Potential Upside/Downside: +42.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-9,840,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -231.29%
• Return on Assets: -54.30%

Debt

• Debt-to-Equity Ratio: 201.47
• Current Ratio: 2.73
• Quick Ratio: 3.52

Sales & Book Value

• Annual Sales: £311,000.00
• Price / Sales: 462.31
• Cash Flow: GBX 69.80 per share
• Price / Cash Flow: 16.08
• Book Value: GBX (41) per share
• Price / Book: -27.38

Miscellaneous

• Outstanding Shares: 12,810,000
• Free Float: N/A
• Market Cap: £143.78 million
• Optionable: Not Optionable
• Beta: 1.09